EGFR/HER2-IN-20

EGFR/HER2-IN-20 (Compound 2b) potently inhibits the proliferation of HeLa and MDA-MB-231 cancer cells, with IC₅₀ values of 3.87 μM and 3.01 μM, respectively; meanwhile, this compound exhibits high selectivity toward WI-38 normal cells, with selectivity indices of 22.27 and 28.63, respectively^[1].
EGFR/HER2-IN-20 induces G1/S phase cell cycle arrest and significant apoptosis in HeLa cells, increasing the proportion of total apoptotic cells to 28.42%. It also alters cell cycle distribution, leading to cell accumulation in the G0/G1 and S phases, while reducing the number of cells in the G2/M phase^[1].
EGFR/HER2-IN-20 (72 h) significantly inhibits the migration of MDA-MB-231 cells and reduces the wound healing rate to 62.96%^[1].
EGFR/HER2-IN-20 upregulates the expression levels of pro-apoptotic proteins BAX and caspase-3 by 7.42-fold and 9.16-fold, respectively, and downregulates the expression level of CCND1 protein to 0.23-fold in HeLa cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.